Matches in SemOpenAlex for { <https://semopenalex.org/work/W2691416280> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2691416280 abstract "Imatinib was the first targeted tyrosine kinase inhibitor (TKI) to be approved for clinical use, and remains first-line therapy for Philadelphia chromosome (Ph+)-positive chronic myelogenous leukaemia (CML). The second-generation inhibitor, nilotinib, was subsequently approved for treatment of CML patients that are resistant, or develop resistance, to imatinib. Imatinib was subsequently approved as front-line therapy for the treatment of gastrointestinal stromal tumours (GISTs), but failed clinical trials for glioblastoma multiforme (GBM). The present study shows that treatment of cultured glioma cells and glioma cells isolated from human biopsies with imatinib or nilotinib strikingly increases tyrosine phosphorylation of p130Cas, focal adhesion kinase (FAK) and paxillin (PXN), resulting in enhanced cell migration and three dimensional radial invasion. Imatinib and nilotinib-induced tyrosine phosphorylation and invasion is dependent on expression of p130Cas and FAK activity, and is not dependent on known imatinib and nilotinib targets including ABL, ARG, platelet derived growth factor receptor (PDGFR) and the collagen receptor DDR1. Interestingly, findings implicate the serine / threonine phosphatase PP2A in mediating tyrosine phosphorylation of p130Cas, FAK and PXN. Inhibition of PP2A with okadaic acid significantly increased basal levels of tyrosine phosphorylation of the three proteins. Conversely, pharmacological activation of PP2A using FTY720 strongly inhibited imatinib and nilotinib stimulated tyrosine phosphorylation. Imatinib and nilotinib also stimulate tyrosine phosphorylation and radial invasion in GIST cells, a cancer for which imatinib is already approved. These TKIs also stimulate tyrosine phosphorylation of p130Cas, FAK and PXN in hepatocellular liver carcinoma cells, and in non-transformed primary cell lines. Interestingly, Imatinib and nilotinib treatment of GBM cells results in increased serine phosphorylation of p130Cas, FAK and PXN. Findings here indicate important and unforeseen adverse effects of imatinib and nilotinib treatment on key motility-related pathways, which could be a significant contributor to the lack of clinical efficacy in GBM and to the development of resistance." @default.
- W2691416280 created "2017-06-30" @default.
- W2691416280 creator A5075111301 @default.
- W2691416280 date "2017-04-28" @default.
- W2691416280 modified "2023-09-23" @default.
- W2691416280 title "Mechanisms of glioblastoma cell migration and invasion: insights from the use of tyrosine kinase inhibitors" @default.
- W2691416280 hasPublicationYear "2017" @default.
- W2691416280 type Work @default.
- W2691416280 sameAs 2691416280 @default.
- W2691416280 citedByCount "0" @default.
- W2691416280 crossrefType "dissertation" @default.
- W2691416280 hasAuthorship W2691416280A5075111301 @default.
- W2691416280 hasConcept C11960822 @default.
- W2691416280 hasConcept C121608353 @default.
- W2691416280 hasConcept C126322002 @default.
- W2691416280 hasConcept C170493617 @default.
- W2691416280 hasConcept C180361614 @default.
- W2691416280 hasConcept C2775960820 @default.
- W2691416280 hasConcept C2777413986 @default.
- W2691416280 hasConcept C2777553839 @default.
- W2691416280 hasConcept C2777583451 @default.
- W2691416280 hasConcept C2778729363 @default.
- W2691416280 hasConcept C2778820342 @default.
- W2691416280 hasConcept C2779536868 @default.
- W2691416280 hasConcept C3019892230 @default.
- W2691416280 hasConcept C42362537 @default.
- W2691416280 hasConcept C502942594 @default.
- W2691416280 hasConcept C71924100 @default.
- W2691416280 hasConcept C86803240 @default.
- W2691416280 hasConcept C95444343 @default.
- W2691416280 hasConceptScore W2691416280C11960822 @default.
- W2691416280 hasConceptScore W2691416280C121608353 @default.
- W2691416280 hasConceptScore W2691416280C126322002 @default.
- W2691416280 hasConceptScore W2691416280C170493617 @default.
- W2691416280 hasConceptScore W2691416280C180361614 @default.
- W2691416280 hasConceptScore W2691416280C2775960820 @default.
- W2691416280 hasConceptScore W2691416280C2777413986 @default.
- W2691416280 hasConceptScore W2691416280C2777553839 @default.
- W2691416280 hasConceptScore W2691416280C2777583451 @default.
- W2691416280 hasConceptScore W2691416280C2778729363 @default.
- W2691416280 hasConceptScore W2691416280C2778820342 @default.
- W2691416280 hasConceptScore W2691416280C2779536868 @default.
- W2691416280 hasConceptScore W2691416280C3019892230 @default.
- W2691416280 hasConceptScore W2691416280C42362537 @default.
- W2691416280 hasConceptScore W2691416280C502942594 @default.
- W2691416280 hasConceptScore W2691416280C71924100 @default.
- W2691416280 hasConceptScore W2691416280C86803240 @default.
- W2691416280 hasConceptScore W2691416280C95444343 @default.
- W2691416280 hasLocation W26914162801 @default.
- W2691416280 hasOpenAccess W2691416280 @default.
- W2691416280 hasPrimaryLocation W26914162801 @default.
- W2691416280 hasRelatedWork W2006734588 @default.
- W2691416280 hasRelatedWork W2008702706 @default.
- W2691416280 hasRelatedWork W2034157904 @default.
- W2691416280 hasRelatedWork W2037711561 @default.
- W2691416280 hasRelatedWork W2064062041 @default.
- W2691416280 hasRelatedWork W2078964293 @default.
- W2691416280 hasRelatedWork W2078994954 @default.
- W2691416280 hasRelatedWork W2131884795 @default.
- W2691416280 hasRelatedWork W2168437437 @default.
- W2691416280 hasRelatedWork W2362074660 @default.
- W2691416280 hasRelatedWork W2415754626 @default.
- W2691416280 hasRelatedWork W2440861704 @default.
- W2691416280 hasRelatedWork W2495419782 @default.
- W2691416280 hasRelatedWork W2514979974 @default.
- W2691416280 hasRelatedWork W2571049132 @default.
- W2691416280 hasRelatedWork W2585541795 @default.
- W2691416280 hasRelatedWork W2795903258 @default.
- W2691416280 hasRelatedWork W2895525604 @default.
- W2691416280 hasRelatedWork W2979743675 @default.
- W2691416280 hasRelatedWork W346965751 @default.
- W2691416280 isParatext "false" @default.
- W2691416280 isRetracted "false" @default.
- W2691416280 magId "2691416280" @default.
- W2691416280 workType "dissertation" @default.